464

Compound name
Tenalisib
Alt Name
RP6530
RP-6530
Compound Image
Tenalisib.png
SMILES
CCC(C1=C(C(=O)C2=CC=CC=C2O1)C3=CC(=CC=C3)F)NC4=NC=NC5=C4NC=N5
MW
415.40
Brutto
C23H18FN5O2
InChI
InChI=1S/C23H18FN5O2/c1-2-16(29-23-19-22(26-11-25-19)27-12-28-23)21-18(13-6-5-7-14(24)10-13)20(30)15-8-3-4-9-17(15)31-21/h3-12,16H,2H2,1H3,(H2,25,26,27,28,29)/t16-/m0/s1
InChI Key
HDXDQPRPFRKGKZ-INIZCTEOSA-N
Approval Jurisdiction
2019 FDA
Approved for clinical use
PTCL, Brest Cancer
CAS
1639417-53-0
PubChem CID
86291103
Action
PI3K δ/ γ
Approved Drug List
1
Commercial Vendor
Rhizen Pharm.